These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


164 related items for PubMed ID: 20727552

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison and characteristics of children successfully treated for daytime urinary incontinence.
    Jessen AS, Hagstroem S, Borch L.
    J Pediatr Urol; 2022 Feb; 18(1):24.e1-24.e9. PubMed ID: 34930690
    [Abstract] [Full Text] [Related]

  • 6. Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial.
    Sillén U, Arwidsson C, Doroszkiewicz M, Antonsson H, Jansson I, Stålklint M, Abrahamsson K, Sjöström S.
    J Pediatr Urol; 2014 Dec; 10(6):1100-5. PubMed ID: 24881806
    [Abstract] [Full Text] [Related]

  • 7. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
    Meijer EF, Nieuwhof-Leppink AJ, Dekker-Vasse E, de Joode-Smink GC, de Jong TP.
    J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rössler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Alloussi S, Bock P, Strugala G, Madersbacher H.
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
    Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF.
    J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
    [Abstract] [Full Text] [Related]

  • 17. Clinical differences in daytime wetting subtypes: urge incontinence and postponed voiding.
    Kuhn S, Natale N, Siemer S, Stoeckle M, von Gontard A.
    J Urol; 2009 Oct; 182(4 Suppl):1967-72. PubMed ID: 19695641
    [Abstract] [Full Text] [Related]

  • 18. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Voiding school as a treatment for daytime incontinence or enuresis: Assessing the effectiveness of intervention by measuring changes in wetting episodes.
    Saarikoski A, Koppeli R, Taskinen S, Axelin A.
    J Pediatr Urol; 2018 Jun; 14(3):256.e1-256.e7. PubMed ID: 29452905
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.